AstraZeneca

49 articles with AstraZeneca

• Juvisé Pharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less Than One Month

  2/4/2020

  Juvisé Pharmaceuticals is pleased to announce its successful syndication of its EUR 213 million debt package supporting the acquisition of Arimidex® and Casodex® from AstraZeneca, with the collaboration of Société Générale and HSBC, acting as Physical Bookrunners and Mandated Lead Arrangers, BNP Paribas, acting as Mandated Lead Arranger and Lazard acting as financial advisor to Juvisé Pharmaceuticals.

• CELLINK announces extension of collaboration with AstraZeneca to use CELLINKs’ 3D-bioprinting and associated technology for drug discovery

  2/3/2020

  CELLINK, focused on the commercialization of innovative technologies for bioprinting and associated technologies for preparation and analysis of 3D-bioprinted tissues, announced today that the company has renewed its agreement to collaborate with the global biopharmaceutical company AstraZeneca for an additional 12 months.

• Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint

  1/27/2020

  Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2 positive metastatic gastric cancer

• FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

  1/21/2020

  AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations,

• My Green Lab Announces Collaboration with AstraZeneca

  1/14/2020

  My Green Lab is pleased to announce a collaboration with AstraZeneca to implement a global-scale green labs program across their research sites as part of their commitment to sustainability, including protecting the environment.

•  FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review

  1/13/2020

  Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in Women Regardless of Their Biomarker Status Who Responded to Platinum-Based Chemotherapy

• Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

  1/8/2020

  Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion

• MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases

  1/7/2020

  MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA molecules in metabolic diseases.

• FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction

  1/6/2020

  AstraZeneca announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for FARXIGA® to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction with and without type 2 diabetes.

• LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

  12/30/2019

  AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA

• LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Cancer

  12/30/2019

  LYNPARZA reduced the risk of disease progression or death by 47% in patients whose disease had not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen 

• Starpharma: Commencement of Phase 1 Trial for AZD0466 Utilising DEP® Delivery Technology

  12/29/2019

  Starpharma announced that AstraZeneca has commenced a phase 1 clinical trial of AZD0466 and the first patient has been successfully dosed.

• Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

  12/23/2019

  Baergic Bio, a Fortress partner company, enters into an agreement with AstraZeneca for AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulator

• ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens

  12/20/2019

  Accelerated Approval of Daiichi Sankyo and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) based on the pivotal DESTINY-Breast01 trial that showed clinically meaningful and durable responses

• The French Speciality Pharmaceutical Company, Juvisé Pharmaceuticals Acquires Two Oncology Products From AstraZeneca in Over 40 Countries

  12/20/2019

  The French speciality pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce the successful completion of a transaction with AstraZeneca, regarding the acquisition of the commercial rights of Arimidex® and Casodex® in a number of European, African and other countries.

• ENHERTU (fam-trastuzumab deruxtecan-nxki) Approved in the US for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens

  12/20/2019

  AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

• AstraZeneca Selects IQVIA OCE to Help Further its Digital Focus

  12/19/2019

  IQVIA™ announced that AstraZeneca has selected IQVIA Technologies’ Orchestrated Customer Engagement platform to further its digital agenda and establish its “Field of the Future.”

• SK Holdings strengthens partnership with AstraZeneca, a global bio-pharmaceutical company

  12/19/2019

  SK Holding's CEO Donghyun Jang met AstraZeneca's Chairman Leif Johansson on December 19th. "We will continue to strengthen the cooperation between the two companies" said Mr. Jang.

• LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemotherapy

  12/17/2019

  Oncologic Drugs Advisory Committee Voted That LYNPARZA Demonstrated a Favorable Benefit-Risk Profile for Patients Based on Phase 3 POLO Trial Results

• DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial

  12/11/2019

  Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today presented positive detailed data from the global pivotal phase 2 single-arm DESTINY-Breast01 trial of DS-8201 ([fam-] trastuzumab deruxtecan), an investigational HER2 targeting antibody drug conjugate (ADC), in patients with HER2 positive metastatic breast cancer.